title: Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
abstract: Here we discuss the case of a heavily pretreated male patient with relapsed-refractory multiple myeloma and previous monoclonal gammopathy of undetermined significance who initiated a fifth-line treatment with pomalidomide (4 mg orally, days 1-21 of a 28-day cycle) and low-dose dexamethasone (40 mg weekly orally). A total of 3 months later, very good partial response was achieved and complete response was maintained for 7 months. This case illustrates the field-practice experience on the benefits of pomalidomide in a relapsed-refractory multiple myeloma patient with a previous history of monoclonal gammopathy of undetermined significance. Indeed, the pomalidomide/dexamethasone regimen resulted in a longer progression-free survival compared with previous regimens and demonstrated a good long-term tolerability.
authors.affiliation: Division of Hematology, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy.
authors.forename: Concetta
authors.initials: C
authors.lastname: Conticello
authors.affiliation: Division of Hematology, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy.
authors.forename: Marina
authors.initials: M
authors.lastname: Parisi
authors.affiliation: Section of Haematology, General Surgery and Medical Specialties, University of Catania, Catania, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Romano
authors.affiliation: Division of Hematology, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy.
authors.forename: Valeria
authors.initials: V
authors.lastname: Calafiore
authors.affiliation: Division of Hematology, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy.
authors.forename: Flavia
authors.initials: F
authors.lastname: Ancora
authors.affiliation: Division of Hematology, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy.
authors.forename: Alessia
authors.initials: A
authors.lastname: La Fauci
authors.affiliation: Division of Hematology, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy.
authors.forename: Maria Letizia
authors.initials: ML
authors.lastname: Consoli
authors.affiliation: Section of Haematology, General Surgery and Medical Specialties, University of Catania, Catania, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Di Raimondo
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D009364:Neoplasm Recurrence, Local; D019233:Retreatment; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D007155:Immunologic Factors; D013792:Thalidomide; C467566:pomalidomide
keywords: complete response; monoclonal gammopathy of undetermined significance; multiple myeloma; pomalidomide; very good partial response